PFSA Stock Chart & Stats
$0.69
--
Market closed
$0.69
--
Day’s Range― - ―
52-Week Range$0.11 - $938.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)11.18M
Market Cap
$533.13K
Enterprise Value$12.30M
Total Cash (Recent Filing)$375.00K
Total Debt (Recent Filing)$12.54M
Price to Earnings (P/E)―
Beta1.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,660,268
10 Day Avg. Volume2,452,317
30 Day Avg. Volume11,175,155
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.10
Price to Sales (P/S)0.00
P/FCF Ratio-0.16
Enterprise Value/Market Cap23.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Profusa News
PFSA FAQ
What was Profusa’s price range in the past 12 months?
Profusa lowest stock price was $0.10 and its highest was $938.25 in the past 12 months.
What is Profusa’s market cap?
Profusa’s market cap is $533.13K.
When is Profusa’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Profusa’s earnings last quarter?
Currently, no data Available
Is Profusa overvalued?
According to Wall Street analysts Profusa’s price is currently Overvalued.
Does Profusa pay dividends?
Profusa does not currently pay dividends.
What is Profusa’s EPS estimate?
Profusa’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Profusa have?
Profusa has 4,660,268 shares outstanding.
What happened to Profusa’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Profusa?
Currently, no hedge funds are holding shares in PFSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Profusa
Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors. These innovative devices, exemplified by their Lumee™ Oxygen Platform, are designed for uninterrupted observation of internal physiological markers. By leveraging artificial intelligence, Profusa translates this constant stream of data into actionable health insights, primarily to empower individuals and clinicians in the management of persistent health challenges like diabetes and critical limb ischemia.
Technical Analysis
Silexion Therapeutics
―
―
CERo Therapeutics Holdings
―
New Era Energy & Digital
―
Beta Bionics, Inc.
―
Ownership Overview
32.41% Insiders
0.13% Mutual Funds
― Other Institutional Investors
67.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---